Advertisement
Adial Pharma Says Purnovate's PNV-6005 Reports Positive Data In Treating Ulcerative Colitis
(RTTNews) - Adial Pharmaceuticals, Inc. (ADIL) announced Tuesday that Purnovate, Inc., a subsidiary of Adial, achieved positive in-vivo data from its study with mice treated with Purnovate's PNV-6005 as a potential treatment for inflammatory bowel diseases.
PNV-6005 is a selective adenosine 2A receptor agonist designed to have anti-inflammatory properties and protective effects against colitis and other inflammatory bowel diseases (IBD).
In the study, PNV-6005 demonstrated statistically significant effect against both primary study endpoints, which are pre-clinical endpoints expected to indicate potential efficacy against ulcerative colitis in humans.
Specially, PNV-6005 significantly prevented weight loss as compared to the control group (greater than 50% inhibition of weight loss). It also significantly prevented colon damage as evidenced by reduction of shortening of colon lengths in the PNV-6005 treated group (almost total prevention), as well as a decrease in inflammation as assessed histologically.
Adial Pharmaceuticals Names Director Tony Goodman As Chief Operating Officer
China Trade Data On Tap For Thursday
U.S. Dollar Drops Against Majors
Swiss Market Ends Notably Lower
European Stocks Close Mostly Higher On Earnings, Fed Rate Cut Hopes
Canadian Stocks Surge Higher Again; TSX Scales New Record High
India Holds Key Interest Rates Steady As Trade Tensions Escalate
